GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma
- PDF / 4,834,234 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 20 Downloads / 131 Views
REVIEW ARTICLE
GliMR: Cross‑Border Collaborations to Promote Advanced MRI Biomarkers for Glioma Patricia Clement1 · Thomas Booth2,3 · Fran Borovečki4 · Kyrre E. Emblem5 · Patrícia Figueiredo6 · Lydiane Hirschler7 · Radim Jančálek8 · Vera C. Keil9 · Camille Maumet10 · Yelda Özsunar11 · Cyril Pernet12 · Jan Petr13 · Joana Pinto14 · Marion Smits15 · Esther A. H. Warnert15 Received: 22 June 2020 / Accepted: 4 November 2020 © The Author(s) 2020
Abstract Purpose There is an annual incidence of 50,000 glioma cases in Europe. The optimal treatment strategy is highly personalised, depending on tumour type, grade, spatial localization, and the degree of tissue infiltration. In research settings, advanced magnetic resonance imaging (MRI) has shown great promise as a tool to inform personalised treatment decisions. However, the use of advanced MRI in clinical practice remains scarce due to the downstream effects of siloed glioma imaging research with limited representation of MRI specialists in established consortia; and the associated lack of available tools and expertise in clinical settings. These shortcomings delay the translation of scientific breakthroughs into novel treatment strategy. As a response we have developed the network “Glioma MR Imaging 2.0” (GliMR) which we present in this article. Methods GliMR aims to build a pan-European and multidisciplinary network of experts and accelerate the use of advanced MRI in glioma beyond the current “state-of-the-art” in glioma imaging. The Action Glioma MR Imaging 2.0 (GliMR) was granted funding by the European Cooperation in Science and Technology (COST) in June 2019. Results GliMR’s first grant period ran from September 2019 to April 2020, during which several meetings were held and projects were initiated, such as reviewing the current knowledge on advanced MRI; developing a General Data Protection Regulation (GDPR) compliant consent form; and setting up the website. Conclusion The Action overcomes the pre-existing limitations of glioma research and is funded until September 2023. New members will be accepted during its entire duration. Keywords Glioma · Advanced MRI · Multi-disciplinary · Networking · Translational research · COST action
1 State‑of‑the‑Art MR Imaging for Glioma In Europe, approximately 50,000 new cases of glioma (brain tumours originating from glial cells) occur each year [1], with numbers constantly rising with an aging European population. Median survival ranges from more than 10 years for low-grade glioma, to only 14.6 months for the most aggressive forms of glioma, namely glioblastoma [2]. Survival increases when the tumour is diagnosed accurately early on and an appropriate course of treatment is applied. However, screening and management are limited due to the heterogeneity in tumour growth dynamics, as well as the high inter- and intra-tumoral biological spatial heterogeneity * Patricia Clement [email protected] Extended author information available on the last page of the article
[3]. Currently, there is increasing interest in
Data Loading...
